J Am Heart Assoc

Triptan initiation linked to higher stroke risk in large migraine cohort

March 17, 2026

In a nationwide, insurance-based cohort study of nearly 870,000 adults with migraine, initiation of a triptan was associated with a significantly higher risk of subsequent cerebrovascular events compared with nonuse. Over a median follow-up of about seven years, triptan initiators had more than double the adjusted risk of cerebral ischemic stroke (adjusted hazard ratio [aHR], 2.37; 95% confidence interval [CI], 1.65-3.51), translating to a small absolute risk increase of approximately 0.17% per year. Triptan initiation was also associated with higher risks of intracranial hemorrhage (aHR, 2.37; 95% CI, 1.65–3.41) and myocardial infarction (aHR, 2.06; 95% CI, 1.60–2.6). The cohort was relatively young (median age, 40 years) and predominantly female, suggesting that even in lower-risk populations, vascular events—while uncommon—may occur more frequently after triptan initiation. As an observational study using claims data, the findings cannot prove causality but add important population-level evidence to long-standing safety concerns.

Clinical takeaway: Before starting a triptan, carefully assess individual vascular risk (including stroke and cardiovascular history), counsel patients on the small but measurable absolute risk, and consider alternative acute migraine therapies in higher-risk patients.

Source:

Kalapura C, et al. (2026, February 12). J Am Heart Assoc. Triptan Initiation and Cerebrovascular Events in Patients With Migraine: A Nationwide Cohort Study. https://pubmed.ncbi.nlm.nih.gov/41676929/